RAAB MICHAEL sold $226K of ARDX

RAAB MICHAEL (President & CEO) sold 58,574 shares of ARDELYX, INC. (ARDX) at $3.86 ($0.23M total) across 4 trades on 2026-08-21.

Original reporting
SEC EDGAR · RAAB MICHAEL
Published Aug 25, 2026, 11:07 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 25, 2026, 11:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ARDX
Bearish
medium confidence
Mentioned
$ARDX
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARDXBearishLow
01

Why it matters

The filing provides the first public record of the CEO's share sale, offering a data point for investors.

02

Market read

Insider sale by the CEO may influence short‑term sentiment but is unlikely to drive major price movement.

03

What to watch

The CEO retains a large stake (over 1.6M shares) and may be diversifying without losing confidence.

Relevance 4/10Novelty 5/10Timing: post‑market filing on 2026‑08‑25

Background

Form 4 filing discloses insider transactions required by the SEC.

Company-level read

Ticker impact

$ARDXBearishMedium confidence
Context

CEO Michael Raab sold 58,574 shares for $225,914 on 2026-08-21.

Expected impact

Potential short‑term pressure on ARDX, modest downside of 1‑2% if market reacts.

Evidence & confidence

The sale size is modest ($226K) relative to holdings, but CEO involvement gives weight to the signal.

Market effects

Minimal impact on the broader biotech sector; insider sales are common and not sector‑wide.

No significant regional effect; the company trades primarily on US exchanges.

Limited global relevance beyond ARDX shareholders.

Counterpoint

The sale could be routine liquidity management rather than a negative signal.

Key entities

  • Michael Raab

    President & CEO of ArdeLynx, Inc.

  • ArdeLynx, Inc.

    Biotech firm listed on NASDAQ under ticker ARDX.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ARDXMed

Ardelyx (ARDX) Q3 2026 Earnings Call Transcript

Ardelyx (ARDX) reported Q3 2026 revenue of $125.5M, up 19% YoY. IBSRELA revenue grew 23% to $96.3M, while XPHOZAH revenue rose 7% to $29.2M. The company reaffirmed its full-year guidance and expects profitability in 2027. Ardelyx has $285.3M in cash and is advancing its ACCEL Phase III trial for chronic idiopathic constipation.

$ARDXLow

Ardelyx Inc (ARDX) (Q3 2026) Earnings Call Highlights: Revenue Climbs 19% as IBSRELA Shines

Ardelyx Inc (ARDX) reported a 19% revenue increase in Q3 2026, driven by its IBSRELA drug. CEO Michael Raab and CFO Sue Hohenleitner addressed prescription trends, payer negotiations, and the company's IBSRELA Pharmacy Network (IPN). They reaffirmed guidance, citing strong fundamentals and positive early indicators from a DTC campaign. The company also discussed its Phase 3 ACCEL trial for CIC and inventory dynamics for XPHOZAH.

$ARDXMedAI 8/10

What Ardelyx (ARDX) Said on Its Q3 Earnings Call

Ardelyx (ARDX) reported Q3 revenue of $29.2M for XPHOZAH, up 7% YoY. Paid prescriptions rose 22%, but demand was offset by customer buying patterns. The company maintained its full-year revenue outlook of $110M-$120M. Ardelyx also launched a direct-to-consumer ad campaign for IBSRELA, with 91% of patients expressing interest. R&D expenses increased to $25.2M, and the company reported a net loss of $700K. Ardelyx expects to reach profitability in 2027, with a gross profit margin exceeding 95%.